Clearpoint Neuro Inc (CLPT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Clearpoint Neuro Inc (CLPT) has a cash flow conversion efficiency ratio of -0.423x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.97 Million) by net assets ($18.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Clearpoint Neuro Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Clearpoint Neuro Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Clearpoint Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Clearpoint Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearpoint Neuro Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Excelsior Medical Co Ltd
TW:4104
|
-0.022x |
|
West Bancorporation
NASDAQ:WTBA
|
0.048x |
|
Emergent Biosolutions Inc
NYSE:EBS
|
-0.065x |
|
Fiducial Real Estate SA
PA:ORIA
|
0.047x |
|
Panoro Energy ASA
F:1PZ
|
0.139x |
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
-0.003x |
|
ICBC Turkey Bank AS
IS:ICBCT
|
1.650x |
|
Plasson Indus
TA:PLSN
|
0.068x |
Annual Cash Flow Conversion Efficiency for Clearpoint Neuro Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Clearpoint Neuro Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Clearpoint Neuro Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.02 Million | $-23.93 Million | -0.854x | -142.22% |
| 2024-12-31 | $25.39 Million | $-8.95 Million | -0.353x | +45.60% |
| 2023-12-31 | $21.17 Million | $-13.72 Million | -0.648x | -47.85% |
| 2022-12-31 | $36.89 Million | $-16.17 Million | -0.438x | -68.41% |
| 2021-12-31 | $48.79 Million | $-12.70 Million | -0.260x | +92.08% |
| 2020-12-31 | $2.38 Million | $-7.81 Million | -3.285x | -428.66% |
| 2019-12-31 | $4.59 Million | $-2.85 Million | -0.621x | +79.72% |
| 2018-12-31 | $1.51 Million | $-4.63 Million | -3.065x | -198.08% |
| 2017-12-31 | $5.83 Million | $-5.99 Million | -1.028x | -113.36% |
| 2016-12-31 | $-756.07K | $-5.82 Million | 7.698x | +76.55% |
| 2015-12-31 | $-1.98 Million | $-8.64 Million | 4.360x | -93.97% |
| 2014-12-31 | $-100.33K | $-7.25 Million | 72.265x | +6249.42% |
| 2013-12-31 | $-6.83 Million | $-7.78 Million | 1.138x | -12.16% |
| 2012-12-31 | $-5.74 Million | $-7.43 Million | 1.296x | +353.61% |
| 2011-12-31 | $-21.84 Million | $-6.24 Million | 0.286x | -- |
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which … Read more